| General Genetic Testing, Somatic Disorders AHS-M2146 |
Reviewed by Avalon 4th Quarter 2021 CAB. Removed items #4 and 5 from the When Covered section, as follows: “MSI testing for all solid tumors is considered medically necessary for individuals being considered for pembrolizumab (Keytruda) therapy, and TMB testing is covered for all solid tumors for individuals being considered for pembrolizumab (Keytruda) therapy.” Description, policy guidelines, and references updated with minor revisions. Added code 0268U and removed 81301 under the Billing/Coding section. Policy noticed 1/25/22 for effective date of 3/31/22. Medical Director review 1/2022. |
Blue Connect